Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBanco Santander Regulatory News (BNC)

Share Price Information for Banco Santander (BNC)

Share Price is delayed by 15 minutes
Get Live Data
1,028.00    -4.00 (-0.39%)
Bid:
1,030.00
Ask:
1,034.00
Spread: 4.00 (0.388%)
Market Cap: £147.51b
BNC Live PriceLast checked at - London Stock Exchange

Intraday Banco Santander Share Chart

Santander AT1 Pre-Stabilisation Notice

26 Sep 2017 08:49

RNS Number : 8130R
Barclays Bank PLC
26 September 2017
 

pre-stabilisation announcement

26 September 2017

 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

 

Banco Santander, S.A.

Stabilisation Notice

 

Barclays Bank PLC (debt syndicate desk; telephone: +44 20 7773 9098) hereby gives notice that the Stabilising Manager named below may stabilise the offer of the following securities in accordance with Commission Delegated Regulation EU 1052/2016 under the Market Abuse Regulation (EU/596/2014).

 

The securities:

Issuer:

Banco Santander, S.A.

Guarantor (if any):

N/A

Aggregate nominal amount:

EUR TBA

Description:

Non-Step Up Non-Cumulative Contingent Convertible Perpetual Preferred Tier 1 Securities

Offer price:

 TBA

Stabilisation:

Stabilisation Manager:

Barclays Bank PLC

 

Stabilisation period expected to start on:

26 September 2017

Stabilisation period expected to end no later than:

25 October 2017

Existence, maximum size and conditions of use of over-allotment facility.

Barclays Bank PLC (or any person acting on behalf of the Stabilising Manager) may over‑allot Preferred Securities or effect transactions with a view to supporting the price of the Preferred Securities at a level higher than that which might otherwise prevail. Any stabilisation action or over‑allotment must be conducted in accordance with all applicable laws and rules.

 

In connection with the offer of the above securities, the Stabilising Manager (or any person acting on behalf of the Stabilising Manager) may over-allot the securities or effect transactions with a view to supporting the price of the securities at a level higher than that which might otherwise prevail. However, stabilisation may not necessarily occur and any stabilisation action, if begun, may cease at any time. Any stabilisation action or over-allotment shall be conducted by the Stabilisation Manager (or any person acting on behalf of the Stabilising Manager) in accordance with all applicable laws and rules.

 

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

This announcement is not being distributed to, and must not be passed on to, the general public in the United Kingdom and is not intended to be an invitation or inducement to engage in investment activity for the purpose of Section 21 of the Financial Services and Markets Act 2000 of the United Kingdom (the "FSMA"). This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons who are investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) of the United Kingdom (the "Order"), high net worth entities falling within Article 49(2)(a) to (d) of the Order or any other persons to whom this announcement for the purposes of Section 21 of the FSMA can otherwise lawfully be distributed (all such persons together being referred to as "relevant persons"), and must not be acted on or relied upon by persons other than relevant persons. Any investment or investment activity to which this announcement relates is available only to and will be engaged in only with relevant persons.

 

The securities to which this announcement relates are not intended to be sold and should not be sold to retail clients in the EEA, as defined in the rules set out in the Product Intervention (Contingent Convertible Instruments and Mutual Society Shares) Instrument 2015, as amended or replaced from time to time, other than in circumstances that do not and will not give rise to a contravention of those rules by any person.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an exemption from registration under such Act. There will be no public offer of securities in the United States or in any other jurisdiction.

 

The securities to which this announcement relates must not be offered, distributed or sold neither in Spain nor to Spanish residents. No publicity of any kind shall be made in Spain.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STADQLBLDKFZBBE
Date   Source Headline
18th Jun 202611:05 amRNSBuyback programme: transactions 11-17June
11th Jun 202611:02 amRNSBuyback programme: transactions 4-10June
10th Jun 20268:35 amRNSResult of Tender Offer
5th Jun 20263:06 pmRNSDirector/PDMR Shareholding
4th Jun 202611:05 amRNSBuyback programme: transactions 28May-3June
1st Jun 20264:47 pmRNSTotal Voting Rights
28th May 20267:00 amRNSAT1s Contingent Convertible securities
27th May 20268:26 amRNSOffer to purchase outstanding instruments
27th May 20268:21 amRNSResumption of the share buyback programme
13th May 20263:03 pmRNSRating granted by Fitch Ratings
6th May 20263:08 pmRNSDirector/PDMR Shareholding
1st May 20267:08 amRNSFurther re: Santander to acquire TSB
30th Apr 20264:59 pmRNSTotal Voting Rights
29th Apr 20267:00 amRNS1Q2026 Financial report & Earnings presentation
29th Apr 20267:00 amRNSFirst Quarter 2026 Results - Press release
24th Apr 202611:14 amRNSBuyback programme: transactions 16-23Apr
23rd Apr 20267:40 amRNSProspectus Exemption
23rd Apr 20267:25 amRNSTemporary suspension of the share buyback program
22nd Apr 202611:09 amRNS1st Quarter 2026 Results Notice
16th Apr 202611:04 amRNSBuyback programme: transactions 8-15Apr
14th Apr 20264:58 pmRNSSantander informs of the MREL determined by SRB
8th Apr 202611:07 amRNSBuyback programme: transactions 26Mar-7Apr
31st Mar 20264:44 pmRNSTotal Voting Rights
27th Mar 20262:26 pmRNS2026 AGM - Resolutions
27th Mar 20267:06 amRNSSantander expects higher profit&reaffirms targets
26th Mar 202610:12 amRNSBuyback programme: transactions 19-25Mar
19th Mar 20265:01 pmRNSDirector/PDMR Shareholding
19th Mar 202611:17 amRNSBuyback programme: transactions 12-18Mar
13th Mar 20264:37 pmRNSDirector/PDMR Shareholding
12th Mar 202611:10 amRNSBuyback programme: transactions 5-11Mar
9th Mar 202611:17 amRNSDirector/PDMR Shareholding
9th Mar 202611:14 amRNSDirector/PDMR Shareholding
6th Mar 20264:18 pmRNSDirector/PDMR Shareholding
5th Mar 202611:16 amRNSBuyback programme: transactions 27Feb-4Mar
4th Mar 20265:58 pmRNSDirector/PDMR Shareholding
2nd Mar 20265:57 pmRNSTotal Voting Rights
27th Feb 202611:18 amRNSBuyback programme: transactions 19-26Feb
25th Feb 20266:01 pmRNSNotice of AGM
25th Feb 20265:20 pmRNS2025 UK Annual Report
25th Feb 20262:19 pmRNSInvestor Day: Group CFO presentation
25th Feb 202612:42 pmRNSInvestor Day: Group CEO presentation
25th Feb 202612:37 pmRNSInvestor Day: Executive chair presentation
25th Feb 20267:03 amRNSStrategic plans, profit forecasts & payout policy
25th Feb 20267:00 amRNSDividend declaration & agreement to call 2026 AGM
24th Feb 20263:05 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:54 pmRNSDirector/PDMR Shareholding
19th Feb 202611:29 amRNSBuyback programme: transactions 12-18Feb
18th Feb 20264:48 pmRNSDirector/PDMR Shareholding
18th Feb 202611:07 amRNSInvestor Day meeting announcement
12th Feb 20263:02 pmRNSBuyback programme: transactions 4-11Feb

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.